A Clinical Study of GeminiOne TEER System for the Treatment of Severe, Symptomatic MR.
NCT ID: NCT07086534
Last Updated: 2025-07-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
15 participants
INTERVENTIONAL
2025-12-15
2031-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Caisson Transcatheter Mitral Valve Replacement (TMVR)
NCT03661398
MitraClip® After Surgical Mitral Valve Repair
NCT02853955
The Multicenter Clinical Trial of a Novel TEER Decive (V-CLASP Trial)
NCT05391802
Feasibility Study of the Tioga TMVR System
NCT06038838
Efficacy of MitraCLip Vs. PASCAL for the TrEAtment of MitraL REgurgiTation in an All-comer Population
NCT06634121
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The GeminiOne TEER System is intended for use in adult patients with severe symptomatic mitral regurgitation (MR) who have suitable anatomy for both device implantation and transfemoral trans-septal access for left atrial delivery.
Key Inclusion Criteria:
Primary MR: Patients must be deemed high-risk for surgical intervention by the site's heart team.
Secondary MR: Patients must have failed to respond to optimal guideline-directed medical therapy (GDMT) for at least one month, and must also have received appropriate coronary revascularization and cardiac resynchronization therapy (CRT), if indicated.
Initially, up to 15 subjects will be treated. The total duration of the study is expected to be approximately 72 months. The enrollment period will span approximately 12 months. Subjects who receive the investigational device will be followed for 60 months post-implantation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Subjects receiving the treatment of GeminiOne TEER system
GeminiOne Transcatheter Edge-to-Edge Repair (TEER) System
The GeminiOne TEER System consists of a TEER clip implant, transcatheter delivery system and a guide sheath.
The clip is made of cobalt-chromium-nickel alloy with a nickel-titanium alloy gripper, covered with a braided mesh of polyethylene terephthalate (PET) materials.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GeminiOne Transcatheter Edge-to-Edge Repair (TEER) System
The GeminiOne TEER System consists of a TEER clip implant, transcatheter delivery system and a guide sheath.
The clip is made of cobalt-chromium-nickel alloy with a nickel-titanium alloy gripper, covered with a braided mesh of polyethylene terephthalate (PET) materials.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subject has severe MR (Grade lll or greater per the ASE criteria, which includes severity grades of 3+ and 4+). Severity grades (3+)/ (4+) MR confirmed by core lab review on transthoracic or transesophageal echocardiography.
For patients with primary mitral regurgitation: Deemed high or prohibitive surgical risk (STS score 8 for valve replacement or \> 6 for valve repair or determined by the site heart team due to documented surgical risk factors) For patients with secondary mitral regurgitation: undergone optimal guideline-directed medical therapy (GDMT) for at least one month as determined by the local heart team; coronary revascularization, and cardiac resynchronization therapy (CRT) if clinically indicated, all of which have proven to be ineffective. Local heart team has determined that mitral valve surgery is not an option.
3. Anatomically suitable for TEER with GeminiOne device as confirmed by site investigators, core lab, and eligibility committee.
4. Feasible transseptal catheterization and femoral vein access.
5. Written informed consent from subject or legal representative.
Exclusion Criteria
2. Leaflet anatomy that precludes optimal positioning of the GeminiOne device, as determined by site investigators, core lab, and eligibility committee.
3. Evidence of severe calcification or significant cleft in the grasping area of the mitral valve leaflets.
4. Left ventricular ejection fraction (LVEF)\< 20%
5. Left ventricular end-systolic diameter(LVESD)\> 60mm
6. Mobile leaflet length less than 10mm
7. Mitral valve effective orifice area (EOA) \< 3.5cm or a high risk of mitral stenosis developing after device implantation, as judged by site investigators, core lab, and eligibility committee.
8. Echocardiographic evidence of intracardiac mass, thrombus, or vegetation.
9. Presence of severe non-mitral valve disease requiring intervention.
10. Severe pulmonary artery hypertension(sPAP \>70mmHg).
11. Severe right ventricular dysfunction. 12, Active endocarditis or history of mitral valve endocarditis. Active rheumatic heart disease or leaflets severely degenerated from rheumatic disease.
13\. Severe untreated coronary artery stenosis requiring revascularization or other cardiovascular disease requiring surgery.
14.Patents with extreme frailty. 15.Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or any other structural heart disease causing heart failure besides dilated cardiomyopathy.
16\. Severe renal insufficiency with estimated glomerular filtration rate (eGFR) \< 25 mL/min.
17\. Blood cachexia including granulocytopenia(WBC\<3x10\^9/L),acute anemia(HB \<90g/L)thrombocytopenia (PLT \<50x10\^9/L), severe coagulopathy, or contraindications to anticoagulant and antiplatelet therapy.
18\. Evidence of an acute myocardial infarction within the past 4 weeks. 19.Evidence of stroke within the prior 90 days. 20. Any percutaneous cardiac intervention, carotid surgery, or any cardiac surgery within 30 days prior to procedure.
21\. Severe symptomatic carotid artery stenosis exceeding 70% confirmed by imaging.
22\. Subjects with underlying medical or psychiatric conditions that may interfere with trial evaluation (e.g. cancer, infection, severe metabolic disease). Additionally, any case deemed unsuitable for the study by the local heart team.
23.Life expectancy of less than 12 months. 24. Participation in another investigational drug or device study within the past 1 month.
25\. Subjects deemed unlikely to complete the trial due to potential non-compliance, as judged by the investigator.
26\. Any anatomic characteristic or presence of atrial septal occluders, which would preclude the performance of the transseptal approach.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sierra Valve LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EFSGemini1US
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.